CA3129581A1 - Conjugues anticorps-medicament comprenant un anticorps contre dlk1 humain et utilisation associee - Google Patents

Conjugues anticorps-medicament comprenant un anticorps contre dlk1 humain et utilisation associee Download PDF

Info

Publication number
CA3129581A1
CA3129581A1 CA3129581A CA3129581A CA3129581A1 CA 3129581 A1 CA3129581 A1 CA 3129581A1 CA 3129581 A CA3129581 A CA 3129581A CA 3129581 A CA3129581 A CA 3129581A CA 3129581 A1 CA3129581 A1 CA 3129581A1
Authority
CA
Canada
Prior art keywords
solvate
pharmaceutically acceptable
antibody
acceptable salt
antibody conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3129581A
Other languages
English (en)
Inventor
Chang Sik Park
Min Ji Choi
Tae Ik JANG
Yun-Hee Park
Ho Young Song
Juyuel BAEK
Sung Min Kim
Hyeun Joung LEE
Ju Young Lee
Hyoung Rae Kim
Kun Jung Lee
Yong Zu Kim
Chang Sun Lee
Jeiwook CHAE
Sang Pil Lee
Ji-Young Shin
Sunha YOON
Yunseon CHOI
Jae Eun Park
Jisu Lee
Bum-Chan PARK
Young Woo Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Legochem Biosciences Inc
Y Biologics Inc
Original Assignee
Legochem Biosciences Inc
Y Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Legochem Biosciences Inc, Y Biologics Inc filed Critical Legochem Biosciences Inc
Priority claimed from PCT/KR2020/003100 external-priority patent/WO2020180121A1/fr
Publication of CA3129581A1 publication Critical patent/CA3129581A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne : de nouveaux conjugués anticorps-médicament (CAM) ciblant DLK1 ; un métabolite pour activer les CAM ; un procédé de production des CAM ; une utilisation des CAM pour traiter ou prévenir des maladies ; et des utilisations des CAM dans la production de médicaments destinés au traitement ou à la prévention de maladies, plus spécifiquement, des maladies hyperprolifératives et/ou angiogéniques comme le cancer. Plus particulièrement, la présente invention concerne un conjugué anticorps-médicament comprenant un anticorps se liant à DLK1 ou un fragment de liaison à l'antigène de celui-ci, et une composition pharmaceutique le comprenant.
CA3129581A 2019-03-06 2020-03-05 Conjugues anticorps-medicament comprenant un anticorps contre dlk1 humain et utilisation associee Pending CA3129581A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR20190025987 2019-03-06
KR10-2019-0025987 2019-03-06
KR1020200027373A KR102503143B1 (ko) 2019-03-06 2020-03-04 인간 dlk1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
KR10-2020-0027373 2020-03-04
PCT/KR2020/003100 WO2020180121A1 (fr) 2019-03-06 2020-03-05 Conjugués anticorps-médicament comprenant un anticorps contre dlk1 humain et utilisation associée

Publications (1)

Publication Number Publication Date
CA3129581A1 true CA3129581A1 (fr) 2020-09-10

Family

ID=72669539

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3129581A Pending CA3129581A1 (fr) 2019-03-06 2020-03-05 Conjugues anticorps-medicament comprenant un anticorps contre dlk1 humain et utilisation associee

Country Status (6)

Country Link
KR (1) KR102503143B1 (fr)
CN (1) CN112135638A (fr)
AU (1) AU2020233532A1 (fr)
CA (1) CA3129581A1 (fr)
IL (1) IL285953A (fr)
SG (1) SG11202108550PA (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111278860B (zh) * 2017-09-08 2024-03-29 Y生物股份有限公司 抗人dlk1的抗体及其用途
AU2019276833A1 (en) 2018-05-29 2020-11-26 Intocell, Inc. Novel benzodiazepine derivatives and uses thereof
WO2023107560A1 (fr) * 2021-12-07 2023-06-15 The Regents Of The University Of California Anticorps dlk1 et méthodes de traitement du cancer
US20230190939A1 (en) * 2021-12-21 2023-06-22 Intocell, Inc. Antibody drug conjugates comprising toxins with polar groups and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101573384B (zh) * 2006-10-27 2013-02-20 健泰科生物技术公司 抗体和免疫偶联物及其用途
MX2010003718A (es) * 2007-10-19 2010-04-21 Genentech Inc Anticuerpos anti-tenb2 producidos por ingenieria de cisteina y conjugados de farmaco y anticuerpo.
ES2527521T3 (es) * 2008-03-17 2015-01-26 Livtech Inc. Anticuerpos antihumanos frente a Dlk-1 que tienen actividad antitumoral
WO2012138102A2 (fr) * 2011-04-04 2012-10-11 한국생명공학연구원 Anticorps humains spécifiques de dlk1 et compositions pharmaceutiques les contenant
CN113599533A (zh) * 2015-11-25 2021-11-05 乐高化学生物科学股份有限公司 包含分支接头的抗体-药物缀合物及其相关方法
TWI822055B (zh) * 2016-11-21 2023-11-11 台灣浩鼎生技股份有限公司 共軛生物分子、醫藥組成物及方法
HUE056289T2 (hu) * 2017-02-08 2022-02-28 Adc Therapeutics Sa Pirrolobenzodiazepin-antitest konjugátumok
WO2018182341A1 (fr) * 2017-03-29 2018-10-04 주식회사 레고켐 바이오사이언스 Précurseur dimère de pyrrolobenzodiazépine et composé conjugué ligand-lieur associé
KR20190018400A (ko) * 2017-08-14 2019-02-22 주식회사 레고켐 바이오사이언스 EGFRvIII에 대한 항체를 포함하는 항체 약물 접합체
CN111278860B (zh) * 2017-09-08 2024-03-29 Y生物股份有限公司 抗人dlk1的抗体及其用途

Also Published As

Publication number Publication date
SG11202108550PA (en) 2021-09-29
KR102503143B1 (ko) 2023-02-24
AU2020233532A1 (en) 2021-09-16
KR20200107837A (ko) 2020-09-16
CN112135638A (zh) 2020-12-25
IL285953A (en) 2021-10-31

Similar Documents

Publication Publication Date Title
EP3936150A1 (fr) Conjugués anticorps-médicament comprenant un anticorps contre dlk1 humain et utilisation associée
US11707533B2 (en) Antibody-drug conjugate comprising antibody against human ROR1 and use for the same
TWI727958B (zh) 抗ｃｄ１２３抗體以及其結合物及衍生物
JP6671555B2 (ja) ピロロベンゾジアゼピン抗体複合体
EP3342785B1 (fr) Linkers pour des conjugués anticorps-médicament
CN107148285B (zh) 吡咯并苯并二氮杂䓬-抗体缀合物
CA3129581A1 (fr) Conjugues anticorps-medicament comprenant un anticorps contre dlk1 humain et utilisation associee
BR112019028295A2 (pt) compostos que compreendem ligante clivável e usos dos mesmos
CA3202759A1 (fr) Conjugues anticorps-medicament inhibiteurs de mcl-1 et procedes d'utilisation
KR20210099658A (ko) 절단가능 링커를 포함하는 화합물 및 이의 용도
KR20210099660A (ko) 절단가능 링커를 포함하는 화합물 및 이의 용도
EP4257606A1 (fr) Préparation et utilisation d'un anticorps anti-fshr et d'un conjugué anticorps-médicament de celui-ci
JP2016511257A (ja) 癌の治療における抗ｇｃｃ抗体−薬物複合体及びｄｎａ損傷剤の投与
RU2801630C2 (ru) Коньюгаты антитело-лекарственное средство, включающие антитело против человеческого dlk1, и их применение
TW202135864A (zh) 包含針對人ｄｌｋ１的抗體的抗體藥物偶聯物及其用途
KR20220158181A (ko) Ror1 및 b7-h3에 결합하는 항체-약물 접합체 및 그 용도
US20240058465A1 (en) Anti-ror1 antibody conjugates, compositions comprising anti ror1 antibody conjugates, and methods of making and using anti-ror1 antibody conjugates
KR20210028556A (ko) 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
KR20210063070A (ko) 항-b7-h3 항체를 포함하는 항체-약물 접합체 및 이의 용도
WO2023194800A1 (fr) Conjugué anticorps-médicament comprenant un anticorps contre le trop2 humain et son utilisation
TW202400266A (zh) 配體藥物偶聯物及其應用
TW202348252A (zh) 用治療性結合分子治療癌症的組合療法
TW202408589A (zh) 抗ror1抗體及抗體結合物、包含抗ror1抗體或抗體結合物之組合物，及製造及使用抗ror1抗體及抗體結合物之方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210809

EEER Examination request

Effective date: 20210809

EEER Examination request

Effective date: 20210809

EEER Examination request

Effective date: 20210809

EEER Examination request

Effective date: 20210809

EEER Examination request

Effective date: 20210809

EEER Examination request

Effective date: 20210809

EEER Examination request

Effective date: 20210809

EEER Examination request

Effective date: 20210809

EEER Examination request

Effective date: 20210809